Prima BioMed Announces Granting of Patent Number US 9,244,059 Eentitled Cytotoxic Anti-LAG-3 Monoclonal Antibody and its Use in the Treatment or Prevention of Organ Transplant Rejection and Autoimmune Disease'
Prima BioMed Ltd (NASDAQ: PBMD)
announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal
antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune
disease" by the United States Patent and Trademark Office.
The patent relates to Prima's IMP731 antibody (originally developed by Immutep).The granted
claims provide protection for specific sequences of the antibody and its use in depleting LAG-3
cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity
Rights for the development of the IMP731 antibody were granted in December 2010 to GSK who
have commenced first-in-human clinical trials of a proprietary antibody (GSK2831781) derived
About IMP731 and GSK2831781
IMP731 and GSK2831781 are designed to specifically deplete potentially pathogenic, recently
activated, LAG-3 expressing T cells which are enriched at the disease site i
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.